Form 4 · Filed Jul 21, 2026, 09:23 PM UTC
ELVN/Enliven Therapeutics, Inc.
Collins Helen Louise — CHIEF MEDICAL OFFICER
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
7 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | M | other | 5,000 | $2 | $12,400 | 30,000 |
| Jul 17, 2026 | S | sell | 231 | $50 | $11,563 | 29,769 |
| Jul 17, 2026 | S | sell | 459 | $52 | $23,660 | 29,310 |
| Jul 17, 2026 | S | sell | 2,063 | $52 | $108,085 | 27,247 |
| Jul 17, 2026 | S | sell | 2,184 | $53 | $116,669 | 25,063 |
| Jul 17, 2026 | S | sell | 63 | $54 | $3,397 | 25,000 |
| Jul 17, 2026 | M | other | 5,000 | — | — | 116,268 |
Source: SEC EDGAR raw filing ↗ · Accession 0001701247-26-000011